Ten years of lung cancer in a single center: gender, histology, stage and survival

Abstract

Aim: The aim was to describe, in a prospective manner, the clinical, histopathological and epidemiological characteristics of lung cancer patients who attended as outpatients at the Lluís Alcanyís, Xàtiva Medical Oncology Hospital, València, Spain from January 2004 to July 2014. We also analyzed survival and compared our data with that reported in the literature.

Methods: Clinical and demographic characteristics were analyzed for the entire series and trends were compared by year of diagnosis. Changes in epidemiology were examined and compared.

Results: There were 701 patients (91.4% were men, mean age 67.6). Main histology was squamous cell carcinoma (41.5%). Squamous cell carcinoma prevailed in men (45.5%) and adenocarcinoma (ADC) in women (60.3%). The percentage of men with lung cancer and of patients with squamous cell carcinoma was higher than in the reported worldwide data and remained throughout the 10 years period. Mean survival was low, with < 10% survivors at 5 years. Stage of disease remained the main prognostic factor for survival.

Conclusion: Squamous cell carcinoma continues to be the most frequent histological type in our area. Male and smoking is associated with lung carcinoma while ADC more often occurs in females. Over the time, our epidemiological and histological patterns have not changed, possibly in relation to maintenance of smoking habits.

Keywords

Epidemiology / histology / lung cancer / smoking / survival

References

[1] Ferlay J,Dikshit R,Mathers C,Parkin DM,Bray F.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012..Int J Cancer2015;136:E359-86

[2] Weir HK,Hankey BF,Howe HL,Jemal A,Anderson RN.Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control..J Natl Cancer Inst2003;95:1276-99

[3] Bach PB,Thornquist MD,Tate RC,Hsieh LJ.Variations in lung cancer risk among smokers..J Natl Cancer Inst2003;95:470-8

[4] Janssen-Heijnen ML.The changing epidemiology of lung cancer in Europe..Lung Cancer2003;41:245-58

[5] Alberg AJ,Samet JM.Epidemiology of lung cancer: looking to the future..J Clin Oncol2005;23:3175-85

[6] Thomas L,Edelman MJ.Lung cancer in women: emerging differences in epidemiology, biology and therapy..Chest2005;128:370-81

[7] Sánchez de Cos Escuín J,Corral Peñafiel J,Sojo González MA.Overall long-term survival in lung cancer analyzed in 610 unselected patients..Arch Bronconeumol2004;40:268-74(in Spanish)

[8] Travis WD,Müller-Hermelink HK.Pathology and genetics of tumours of the lung, pleura, thymus and heart..Lyon: IARC Press;2004;

[9] Cadioli A,Costantini M,Migaldi M.Lung cancer histologic and immunohistochemical heterogeneity in the era of molecular therapies: analysis of 172 consecutive surgically resected, entirely sampled pulmonary carcinomas..Am J Surg Pathol2014;38:502-9

[10] Choy B,Li F,Yang Q.High frequency of coexpression of maspin with p63 and p53 in squamous cell carcinoma but not in adenocarcinoma of the lung..Int J Clin Exp Pathol2013;6:2542-7

[11] Montezuma D,Lopes P,Cunha AL.A panel of four immunohistochemical markers (CK7, CK20, TTF-1 and p63) allows accurate diagnosis of primary and metastatic lung carcinoma on biopsy specimens..Virchows Arch2013;463:749-54

[12] Goldstraw P,Chansky K,Groome PA,Postmus PE,Sobin L.The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours..J Thorac Oncol2007;2:706-14

[13] Gironés R,Gómez-Codina J,Tenias JM.Lung cancer chemotherapy decisions in older patients: the role of patient preference and interactions with physicians..Clin Transl Oncol2012;14:183-9

[14] Gironés R,Gómez-Codina J,Tenias JM.Prognostic impact of comorbidity in elderly lung cancer patients: use and comparison of two scores..Lung Cancer2011;72:108-13

[15] Gironés R,Díaz-Beveridge R.Comorbidity disability and geriatric syndromes in elderly breast cancer survivors. Results of a single-center experience..Crit Rev Oncol Hematol2010;73:236-45

[16] Gironés R,Maestu I,Tenias JM.Comprehensive Geriatric Assessment (CGA) of elderly lung cancer patients: A single-center experience..J Geriatr Oncol2012;3:98-103

[17] Santos-Martínez MJ,Blanco ML,Mojal S,Broquetas JM.Lung cancer at a university hospital: epidemiological and histological characteristics of a recent and historical series..Arch Bronconeumol2005;41:307-12(in Spanish)

[18] Sánchez de Cos Escuín J,Abal Arca J,Hernández Hernández J,Muñoz Gutiérrez FJ,Alonso MA,Allende González J.The EpicliCP-2003 study: A multicenter epidemiological and clinical study of lung cancer in Spain..Arch Bronconeumol2006;42:446-52(in Spanish)

[19] Miravet L,Paradís A,Cabadés F.Epidemiological study of lung cancer in the northern part of the province of Castellón..Arch Bronconeumol2001;37:298-301(in Spanish)

[20] Hernández IS,Sánchez CA.Epidemiology of lung cancer in Spain and forecast for the future..Arch Bronconeumol2006;42:594-9(in Spanish)

[21] National Cancer Institute. Non-Small Cell Lung Cancer Treatment (PDQ®): General Information About Non-Small Cell Lung Cancer (NSCLC). Available from: http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/healthprofessional. [Last Accessed on 2011 Nov 07].

[22] American Cancer Society.Cancer facts and figures..2013;AtlantaAmerican Cancer Society

[23] Salmerón D,Isabel Izarzugaza M,Marcos-Gragera R,Galceran J,Navarro C.Lung cancer prognosis in Spain: the role of histology, age and sex..Respir Med2012;106:1301-8

[24] Navarro C,Ardanaz E,Izarzugaza I,Martínez C.Population-based cancer registries in Spain and their role in cancer control..Ann Oncol2010;21:iii3-13

[25] Montero C,Otero I,Rodríguez G,Pita S.Lung cancer in the health care area of A Coruña (Spain): incidence, clinical approach and survival..Arch Bronconeumol2003;39:209-16(in Spanish)

[26] Alonso-Fernández MA,Escudero-Bueno C.Characteristics of lung cancer in a region in northern Spain..Arch Bronconeumol2005;41:478-83(in Spanish)

[27] Hernández-Hernández JR,Cordovilla-Pérez MR,Bollo De Miguel E.Incidence of bronchopulmonary cancer in Castilla y Leon and Cantabria in the year 2007. A study by the Castilla y Leon and Cantabria Respiratory Diseases Society (SOCALPAR)..Arch Bronconeumol2010;46:7-14(in Spanish)

[28] Lortet-Tieulent J,Ferlay J,Weiderpass E.International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women..Lung Cancer2014;84:13-22

[29] Gironés Sarrió R,López P,Rosell R.Smoking habits in elderly lung cancer patients: still no changes in epidemiology? A single-center experience..Clin Transl Oncol2010;12:686-91

[30] Subramanian J.Lung cancerin never smokers: a review..J Clin Oncol2007;25:561-70

[31] Henschke CL,Miettinen OS.Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer..JAMA2006;296:180-4

[32] Gray N.The consequences of the unregulated cigarette..Tob Control2006;15:405-8 PMCID:PMC2563653

[33] Shepherd FA,Ciuleanu T,Hirsh V,Campos D,Smylie M,van Kooten M,Findlay B,Johnston D,Clark G,Seymour L.Erlotinib in previously treated non-small-cell lung cancer..N Engl J Med2005;353:123-32